Dermal Fillers
YVOIRE references stocked by ALLPARA for professional use, sourced direct and certified on every shipment.
CE Marked
SKU 11240
Yvoire Y-Solution 540
In stock
Volume
1 x 1 mL
Laboratory
LG Chem
Origin
South Korea
Indication
Cross-linked HA dermal filler
Treatment areas
Trade price and history are verified-only
allpara supplies licensed practitioners. Sign in or apply for a B2B account to see live pricing, volume tiers and price history.
Yvoire Y-Solution 540 is a cross-linked hyaluronic acid dermal filler by YVOIRE, developed for aesthetic corrections that call for projection the face can move with. It is typically chosen by clinics, aesthetic physicians and dermatologists for anti-ageing correction and facial projection support, where a balance of elasticity and cohesion matters more than static filling. The product incorporates 20 mg/mL of cross-linked hyaluronic acid with 0.3% lidocaine, is supplied as one 1 mL syringe with two Terumo thin-wall 27G needles enclosed, and is CE-marked for professional use by qualified practitioners only.
Key Benefits of Yvoire Y-Solution 540
- Balances elasticity and cohesion, which the manufacturer describes as giving the gel spring-like characteristics
- Delivers visible projection while adapting to the dynamics of facial expression
- Contains cross-linked hyaluronic acid at 20 mg/mL, a higher concentration than the 360 reference in the same range
- Includes 0.3% lidocaine, intended to improve patient comfort during injection
- Supplied with two Terumo thin-wall 27G needles
- Supports anti-ageing aesthetic correction and facial balancing
- CE-marked medical device
- Part of the Y-Solution 360, 540 and 720 range
Indications and Professional Use
Main indications
- Anti-ageing aesthetic treatment
- Facial projection support
- Treatments requiring a balance of elasticity and cohesion
- Correction of moderate to deep volume loss
Professional use
Yvoire Y-Solution 540 is a sterile, single-use injectable medical device supplied for administration by qualified medical practitioners only. Each syringe is intended for a single patient in a single session; any residual product must be discarded and never retained for reuse. Administration requires an aseptic technique and practitioner competence in facial anatomy and in the management of vascular complications, including intravascular occlusion. Patients must be screened for sensitivity to amide-type local anaesthetics before treatment because the formulation contains lidocaine. The full contraindication, warning and precaution set governing use is the manufacturer's Instructions For Use, and that document takes precedence over any information presented here. The product is not intended for retail supply or for self administration.
Treatment areas
- Midface
- Facial balancing and structural support
Patient profile
Suitable for adult patients seeking correction of age-related volume loss or facial projection support, with suitability determined by the treating practitioner following clinical assessment. Selection should account for skin quality, degree of volume deficit and the mobility of the treated region, since this reference is formulated for areas subject to facial expression. Patients with a known hypersensitivity to hyaluronic acid preparations or to amide-type local anaesthetics such as lidocaine should not be treated. Treatment of pregnant or breastfeeding patients, patients with active infection or inflammation at the intended site, and patients with a history of severe allergy or anaphylaxis is governed by the manufacturer's contraindication list.
How Yvoire Y-Solution 540 Works
Yvoire Y-Solution 540, listed by some suppliers simply as Yvoire 540, works through cross-linked hyaluronic acid at 20 mg/mL, formulated so that elasticity and cohesion are balanced rather than traded against each other. The intended behaviour is spring-like: the gel holds projection under load but flexes as the face moves, which is why the Y-Solution range is positioned around projection that survives expression rather than around static volume. At 20 mg/mL this reference is a firmer gel than the 12 mg/mL 360, and the enclosed 27G needles reflect that heavier body. The 0.3% lidocaine acts locally to reduce discomfort during injection and does not contribute to the filling effect.
Why Order From Allpara
Allpara offers genuine, verified YVOIRE products from vetted suppliers, with full batch-traceability and expert support. We serve clinics and aesthetic professionals with CE-certified products, fast EU-wide delivery from our EU warehouse, and competitive trade pricing. Our focus is your patients' safety, satisfaction and results - with dedicated after-sales support for your peace of mind.
Frequently Asked Questions
Is Yvoire 540 the same product as Yvoire Y-Solution 540?
Yes. Yvoire 540 is a shortened supplier listing of the same reference, and Yvoire Y Solution 540 is the same name written without the hyphen. The official product name is Yvoire Y-Solution 540, and that is the reference supplied by Allpara.
How does Yvoire Y-Solution 540 differ from the 360 and 720 references?
Yvoire Y-Solution 540 contains 20 mg/mL of cross-linked hyaluronic acid and is supplied with 27G needles, whereas the 360 reference contains 12 mg/mL and is supplied with finer 29G needles. All three references share the same balance of elasticity and cohesion; the 540 sits between the 360 and the 720 in the range.
Does Yvoire Y-Solution 540 contain lidocaine?
Yes. The formulation contains 0.3% lidocaine alongside 20 mg/mL of cross-linked hyaluronic acid. Patients should be screened for sensitivity to amide-type local anaesthetics before treatment.
Which needles are supplied with Yvoire Y-Solution 540?
Two Terumo thin-wall 27G needles are enclosed with the single 1 mL syringe.
How long do the results of Yvoire Y-Solution 540 last?
No duration is published by the manufacturer in the documentation held on file. Secondary sources commonly report 6 to 12 months, and others report longer, so the figure should be confirmed against the Instructions For Use before it is quoted to a patient .
Is Yvoire Y-Solution 540 CE-marked?
Yes. The product is CE-marked and classified as a medical device. The specific device class and Notified Body are not stated in the documentation held on file .
More from LG Chem
Clinic alternatives
Mesotherapy
Skin Boosters
/ Recently viewed
Pick up where you left off
Yvoire Y-Solution 540
In stock
CE Marked
Yvoire Y-Solution 540 is a cross-linked hyaluronic acid dermal filler by YVOIRE, developed for aesthetic corrections that call for projection the face can move with. It is typically chosen by clinics, aesthetic physicians and dermatologists for anti-ageing correction and facial projection support, where a balance of elasticity and cohesion matters more than static filling. The product incorporates 20 mg/mL of cross-linked hyaluronic acid with 0.3% lidocaine, is supplied as one 1 mL syringe with two Terumo thin-wall 27G needles enclosed, and is CE-marked for professional use by qualified practitioners only.
Key Benefits of Yvoire Y-Solution 540
- Balances elasticity and cohesion, which the manufacturer describes as giving the gel spring-like characteristics
- Delivers visible projection while adapting to the dynamics of facial expression
- Contains cross-linked hyaluronic acid at 20 mg/mL, a higher concentration than the 360 reference in the same range
- Includes 0.3% lidocaine, intended to improve patient comfort during injection
- Supplied with two Terumo thin-wall 27G needles
- Supports anti-ageing aesthetic correction and facial balancing
- CE-marked medical device
- Part of the Y-Solution 360, 540 and 720 range
Indications and Professional Use
Main indications
- Anti-ageing aesthetic treatment
- Facial projection support
- Treatments requiring a balance of elasticity and cohesion
- Correction of moderate to deep volume loss
Professional use
Yvoire Y-Solution 540 is a sterile, single-use injectable medical device supplied for administration by qualified medical practitioners only. Each syringe is intended for a single patient in a single session; any residual product must be discarded and never retained for reuse. Administration requires an aseptic technique and practitioner competence in facial anatomy and in the management of vascular complications, including intravascular occlusion. Patients must be screened for sensitivity to amide-type local anaesthetics before treatment because the formulation contains lidocaine. The full contraindication, warning and precaution set governing use is the manufacturer's Instructions For Use, and that document takes precedence over any information presented here. The product is not intended for retail supply or for self administration.
Treatment areas
- Midface
- Facial balancing and structural support
Patient profile
Suitable for adult patients seeking correction of age-related volume loss or facial projection support, with suitability determined by the treating practitioner following clinical assessment. Selection should account for skin quality, degree of volume deficit and the mobility of the treated region, since this reference is formulated for areas subject to facial expression. Patients with a known hypersensitivity to hyaluronic acid preparations or to amide-type local anaesthetics such as lidocaine should not be treated. Treatment of pregnant or breastfeeding patients, patients with active infection or inflammation at the intended site, and patients with a history of severe allergy or anaphylaxis is governed by the manufacturer's contraindication list.
How Yvoire Y-Solution 540 Works
Yvoire Y-Solution 540, listed by some suppliers simply as Yvoire 540, works through cross-linked hyaluronic acid at 20 mg/mL, formulated so that elasticity and cohesion are balanced rather than traded against each other. The intended behaviour is spring-like: the gel holds projection under load but flexes as the face moves, which is why the Y-Solution range is positioned around projection that survives expression rather than around static volume. At 20 mg/mL this reference is a firmer gel than the 12 mg/mL 360, and the enclosed 27G needles reflect that heavier body. The 0.3% lidocaine acts locally to reduce discomfort during injection and does not contribute to the filling effect.
Why Order From Allpara
Allpara offers genuine, verified YVOIRE products with full batch-traceability, CE-certified stock, fast EU-wide delivery and expert after-sales support.
Frequently Asked Questions
Is Yvoire 540 the same product as Yvoire Y-Solution 540?
Yes. Yvoire 540 is a shortened supplier listing of the same reference, and Yvoire Y Solution 540 is the same name written without the hyphen. The official product name is Yvoire Y-Solution 540, and that is the reference supplied by Allpara.
How does Yvoire Y-Solution 540 differ from the 360 and 720 references?
Yvoire Y-Solution 540 contains 20 mg/mL of cross-linked hyaluronic acid and is supplied with 27G needles, whereas the 360 reference contains 12 mg/mL and is supplied with finer 29G needles. All three references share the same balance of elasticity and cohesion; the 540 sits between the 360 and the 720 in the range.
Does Yvoire Y-Solution 540 contain lidocaine?
Yes. The formulation contains 0.3% lidocaine alongside 20 mg/mL of cross-linked hyaluronic acid. Patients should be screened for sensitivity to amide-type local anaesthetics before treatment.
Which needles are supplied with Yvoire Y-Solution 540?
Two Terumo thin-wall 27G needles are enclosed with the single 1 mL syringe.
How long do the results of Yvoire Y-Solution 540 last?
No duration is published by the manufacturer in the documentation held on file. Secondary sources commonly report 6 to 12 months, and others report longer, so the figure should be confirmed against the Instructions For Use before it is quoted to a patient .
Is Yvoire Y-Solution 540 CE-marked?
Yes. The product is CE-marked and classified as a medical device. The specific device class and Notified Body are not stated in the documentation held on file .
More from LG Chem
View laboratory →* Professional-use product. Packaging may vary by batch or market. Refer to the supplied IFU for full directions and contraindications.